- Net Income: Biocon’s net income for Q1 is 6.6 billion rupees, a significant increase compared to 1.01 billion rupees last year, and well above the estimated 1.69 billion rupees.
- Revenue: The company reported revenues of 34.3 billion rupees, a slight increase of 0.3% year-over-year but below the estimated 39.5 billion rupees.
- Generics Revenue: Revenue from generics decreased by 5.9% year-over-year to 6.59 billion rupees, falling short of the estimated 7.24 billion rupees.
- Biosimilars Revenue: Biosimilars revenue increased by 3.5% year-over-year to 20.8 billion rupees, although it missed the estimates of 21.75 billion rupees.
- Research Services Revenue: The research services segment saw a 2.2% decrease in revenue, totaling 7.9 billion rupees, lower than the estimated 8.92 billion rupees.
- Total Costs: Total costs for the company rose by 4.5% year-over-year to 34.5 billion rupees.
- Finance Costs: Finance costs were 2.36 billion rupees, a 1.3% increase year-over-year, slightly above the estimate of 2.25 billion rupees.
- Other Income: The company reported other income of 11.3 billion rupees for Q1, primarily from Bicara, compared to 935 million rupees last year.
- Analyst Ratings: The stock has received 7 buy ratings, 3 hold ratings, and 7 sell ratings.
A look at Biocon Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
With a high Value score of 4 and strong Momentum score of 4, the long-term outlook for Biocon Ltd appears promising. As an integrated biotechnology company, Biocon is well-positioned to deliver solid returns to investors due to its attractive valuation and positive market momentum. Additionally, the company’s focus on innovation and growth, reflected in its Growth score of 3, provides further upside potential.
While Biocon’s Dividend score of 2 indicates a lower dividend yield compared to some other companies, its Resilience score of 3 suggests the company has a stable operating environment. Overall, Biocon Ltd‘s diversified portfolio of pharmaceutical products, specialty enzymes, and research services underscores its position as a versatile player in the biotechnology sector with a favorable long-term outlook.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
